...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Food and Drug Law Journal >How FDA Could Use Its Existing Authorities to Make State Legalization of Cannabis More Safe and Effective
【24h】

How FDA Could Use Its Existing Authorities to Make State Legalization of Cannabis More Safe and Effective

机译：FDA如何使用其现有权限来使大麻的合法化更安全有效

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

FDA has been giving state-legalized cannabis products a free pass. Although the federal government has chosen not to enforce its strong anti-drug laws against state-legalized cannabis products, many of those cannabis products are being labeled, advertised, or otherwise marketed and used in ways that make them medical drugs that have failed to secure legally required FDA drug approvals. In addition, any state-legalized cannabis products that were not unapproved medical drugs would likely qualify as supplements, foods, cosmetics, or tobacco products that have largely failed to comply with related Federal Food, Drug, and Cosmetic Act provisions and FDA regulations. Consistent with the current federal policy of tolerance (despite federal laws making cannabis distribution and sale illegal), FDA could use its existing authorities to make state cannabis legalization less harmful and risky to the public health without interfering with any states' ability to achieve its legalization policy goals. By thoughtfully exercising its enforcement discretion, FDA could make the labeling and marketing of state-legalized cannabis products more accurate, less misleading, and less troublesome for the public health. Going further, FDA could stop state-legalized cannabis from being offered in forms that are more harmful, addictive, or attractive to youth than the cannabis products typically offered in illicit markets. Through such an approach, FDA would be honoring its public health mission and protecting the integrity of our federal systems for regulating drugs, tobacco products, supplements, foods, and cosmetics. It would also do far more than current federal policies and practices to reduce some of the most serious and unnecessary public health risks from state cannabis legalization, which both supporters and opponents of cannabis legalization should welcome.
机译：FDA一直在提供国家合法化的大麻产品免费通过。虽然联邦政府选择不加强其对国家合法化的大麻产品的强有力的反毒品法，但许多大麻产品正在被标记，广告或以其他方式销售，并以使其未能确保的医疗药物的方式使用合法要求FDA药物批准。此外，任何未经批准的医疗药物的任何国家合法化的大麻产品都可能有资格作为在主要未能遵守相关联邦食品，药物和美容法案和FDA规定的补充剂，食品，化妆品或烟草产品。符合目前的公差政策（尽管联邦法律使大麻分销和销售非法），FDA可以利用其现有的当局使国家大麻合法化对公共卫生的危险性和风险风险不足，而不会干扰任何国家实现其合法化的能力政策目标。通过若有所思地行使执法自由裁量权，FDA可以使国家合法化的大麻产品的标签和销售更准确，更少误导，对公共卫生的麻烦不那么麻烦。进一步越来越讨论，FDA可以阻止国家合法化的大麻，以更具有害，上瘾或对青少年更具有害，上瘾或有吸引力的形式，而不是通常在非法市场中提供的大麻产品。通过这种方法，FDA将履行其公共卫生使命，并保护我们联邦系统的诚信调节药物，烟草制品，补充剂和化妆品。它还比目前的联邦政策和实践更加差不多，以减少国家大麻合法化的一些最严重和不必要的公共卫生风险，这两个人都欢迎支撑者和法令合法化的支持者和反对者。

著录项

  • 来源
    《Food and Drug Law Journal》 |2019年第2期|共21页
  • 作者

    Lindblom Eric N.;

  • 作者单位

    Georgetown Laws ONeill Inst Natl &

    Global Hlth La Tobacco Control &

    Food &

    Drug Law Washington DC 20001 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 食品工业;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号